肺癌中的表皮生长因子受体抑制剂：小分子还是大分子，选择人群还是未选择人群？ - Suppr

Suppr

超能文献

Epidermal growth factor receptor inhibitors in lung cancer: smaller or larger molecules, selected or unselected populations?

作者信息

Hirsch Fred R, Bunn Paul A

出版信息

J Clin Oncol. 2005 Dec 20;23(36):9044-7. doi: 10.1200/JCO.2005.03.6129. Epub 2005 Nov 21.

DOI:10.1200/JCO.2005.03.6129

PMID:16301593

Abstract

摘要

相似文献

Epidermal growth factor receptor inhibitors in lung cancer: smaller or larger molecules, selected or unselected populations?肺癌中的表皮生长因子受体抑制剂：小分子还是大分子，选择人群还是未选择人群？

J Clin Oncol. 2005 Dec 20;23(36):9044-7. doi: 10.1200/JCO.2005.03.6129. Epub 2005 Nov 21.

Can acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors be overcome by different small-molecule tyrosine kinase inhibitors?不同的小分子酪氨酸激酶抑制剂能否克服对表皮生长因子受体酪氨酸激酶抑制剂的获得性耐药？

J Clin Oncol. 2007 Jun 20;25(18):2504-5. doi: 10.1200/JCO.2007.11.3258.

Autophagy facilitates the EGFR-TKI acquired resistance of non-small-cell lung cancer cells.自噬促进非小细胞肺癌细胞对表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）的获得性耐药。

J Formos Med Assoc. 2014 Mar;113(3):141-2. doi: 10.1016/j.jfma.2012.10.017. Epub 2013 Jan 2.

[Erlotinib in the treatment of non-small cell lung cancer].[厄洛替尼治疗非小细胞肺癌]

Magy Onkol. 2006;50(3):237-41. Epub 2006 Nov 12.

Modern treatment of lung cancer: case 2. Response to erlotinib after failure of gefitinib in a patient with advanced non-small-cell lung carcinoma.肺癌的现代治疗：病例2。一名晚期非小细胞肺癌患者在吉非替尼治疗失败后对厄洛替尼的反应。

J Clin Oncol. 2005 Oct 20;23(30):7738-40. doi: 10.1200/JCO.2005.02.4471.

Epidermal growth factor receptor tyrosine kinase inhibitors plus chemotherapy: case closed or is the jury still out?表皮生长因子受体酪氨酸激酶抑制剂联合化疗：结案了还是仍有待裁决？

J Clin Oncol. 2005 Sep 1;23(25):5856-8. doi: 10.1200/JCO.2005.05.030. Epub 2005 Jul 25.

Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.非小细胞肺癌对表皮生长因子受体酪氨酸激酶抑制剂的获得性耐药

Respir Investig. 2014 Mar;52(2):82-91. doi: 10.1016/j.resinv.2013.07.007. Epub 2013 Aug 30.

Epidermal growth factor receptor tyrosine kinase inhibitors and depression.表皮生长因子受体酪氨酸激酶抑制剂与抑郁症

J Clin Oncol. 2009 Aug 10;27(23):e49-50; author reply e51. doi: 10.1200/JCO.2009.22.5219. Epub 2009 Jul 13.

EGFR inhibitors in the treatment of lung cancer.

Onkologie. 2007 Oct;30(10):476. doi: 10.1159/000107938. Epub 2007 Sep 21.

Nutritional status in the era of target therapy: poor nutrition is a prognostic factor in non-small cell lung cancer with activating epidermal growth factor receptor mutations.靶向治疗时代的营养状况：营养不良是表皮生长因子受体激活突变的非小细胞肺癌的一个预后因素。

Korean J Intern Med. 2016 Nov;31(6):1140-1149. doi: 10.3904/kjim.2015.062. Epub 2016 Mar 28.

引用本文的文献

Molecular predictors of response to tyrosine kinase inhibitors in patients with Non-Small-Cell Lung Cancer.非小细胞肺癌患者对酪氨酸激酶抑制剂反应的分子预测因子。

J Exp Clin Cancer Res. 2012 Sep 19;31(1):77. doi: 10.1186/1756-9966-31-77.

Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC.非小细胞肺癌中的体细胞表皮生长因子受体（EGFR）突变与酪氨酸激酶抑制剂的疗效

Nat Rev Clin Oncol. 2009 Jun;6(6):352-66. doi: 10.1038/nrclinonc.2009.62.

Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells.成纤维细胞生长因子（FGF）和成纤维细胞生长因子受体介导的非小细胞肺癌细胞自分泌信号传导

Mol Pharmacol. 2009 Jan;75(1):196-207. doi: 10.1124/mol.108.049544. Epub 2008 Oct 10.

KRAS mutations: an old oncogene becomes a new predictive biomarker.KRAS突变：一个古老的癌基因成为一种新的预测性生物标志物。

J Mol Diagn. 2008 Nov;10(6):493-5. doi: 10.2353/jmoldx.2008.080105. Epub 2008 Oct 2.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验